Cancer patients, especially those with metastatic disease, are at high risk for skeletal-related events (SREs) such as fractures, spinal cord compression, and severe pain. Ibandronate has been shown to significantly reduce the incidence of these SREs, improving the quality of life for these patients. It is particularly effective in managing bone pain and reducing the need for radiation therapy to bone.
